A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)

This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
In Phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants.
In the event that the stage gate for Phase 2B is reached, then Phase 2B will assesses efficacy and longer-term safety in a larger study group, i.e., 414.

开始日期2021-11-15

申办/合作机构

Vivoryon Therapeutics NV

[+1]

NCT02389413

/ Completed临床2期

A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease

The aim of this study is to evaluate the safety, tolerability and preliminary efficacy of PQ912 in subjects with Mild Cognitive Impairment (MCI) due to Alzheimers Disease (AD) or mild dementia due to AD.

开始日期2015-03-01

申办/合作机构

Vivoryon Therapeutics NV

[+1]

NCT02190708

/ Completed临床1期

A Phase I, Open Label Study to Assess the Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole in Healthy Male Subjects

Midazolam is a rapid-acting benzodiazepine, with a short half-life (approximately 1.9 hours) and is primarily metabolised by CYP3A.
Omeprazole is a selective proton pump inhibitor substrate used to reduce gastric acid secretion. Omeprazole is primarily metabolised by CYP2C19.
Midazolam and omeprazole are both used as probe drugs in clinical pharmacology studies to evaluate clinical CYP3A and CYP2C19 drug interactions, respectively. Furthermore the EMA and the FDA guidance on drug interactions recommend the use of these drugs for such evaluations.
The aim of this study is to assess the effect of PQ912 on the PK of midazolam and omeprazole. In vitro studies have demonstrated that PQ912 inhibits several CYP enzymes, including CYP3A4 and CYP2C19 and at the expected exposure levels in patients, has the potential to inhibit these enzymes in-vivo. This study is therefore planned to investigate the potential changes in the PK of midazolam and omeprazole due to the effect of PQ912 at steady-state. In clinical practice it is likely that co-administration of PQ912 with other drugs that are metabolised via the CYP3A and/or CYP2C19 enzymes will occur. This study will provide important information for the requirement of dose adjustments or contraindications in these circumstances.

开始日期2014-06-01

申办/合作机构

Vivoryon Therapeutics NV

[+1]

100 项与 Varoglutamstat 相关的临床结果

登录后查看更多信息

100 项与 Varoglutamstat 相关的转化医学

登录后查看更多信息

100 项与 Varoglutamstat 相关的专利（医药）

登录后查看更多信息

项与 Varoglutamstat 相关的文献（医药）

2025-12-01·Alzheimers & Dementia

Generalizability of digital speech and language assessments in MCI/mild AD across four non‐English languages

Article

作者: Schaeffer, Michael ; Xu, Mengdan ; Cormack, Francesca K ; Wenzkowski, Christine ; Lillo, Martina De ; Fuchs, Katharina ; Spilka, Michael J. ; Robin, Jessica

Abstract:

Background:

Neurodegenerative diseases affect speech production. Previous studies show various acoustic and linguistic changes in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) speech patterns, such as more pauses and lower usage of nouns. However, most research has focused on English speakers. This analysis examines speech features in MCI and AD patients across four languages to determine if digital speech assessments yield comparable results across different languages.

Method:

This study included 244 patients with MCI or mild AD enrolled in the Phase 2b VIVIAD trial of varoglutamstat, in four language groups: Danish ( n =84), German ( n =59), Dutch ( n =40), and Spanish ( n =61). A picture description task was administered to all patients at baseline using instructions in their respective languages. Five speech features including number of picture objects described, number of nouns, speech rate, pronoun‐to‐noun ratio and average of word length were chosen based on previous analyses of speech patterns in MCI/AD, and a composite score was calculated combining the five measures. We tested the interrelationships among the features in each language and examined whether the speech features were related to another measure of cognitive function, the Mini‐Mental State Exam (MMSE). Associations were examined using a correlational approach.

Result:

There was variation in the magnitudes of the correlations between speech features in the different languages, but the directions of the associations were generally consistent across the four languages in the study. In all four languages, significant correlations with the MMSE were found with both the composite score (‐0.46 ≤ r ≤ ‐0.26) and the object content score (0.27 ≤ r ≤ 0.42).

Conclusion:

Together, these results indicate that there are consistent interrelationships among different speech features across languages. In addition, in the four languages examined, the speech composite score and the number of objects correctly described related to a standard measure of cognition, the MMSE. These results suggest that digital measures of speech and language in MCI/AD are generalizable across languages and relate to cognitive ability more generally. In addition, a composite score of multiple speech features may be more sensitive to cognitive impairment than individual speech metrics.

2025-12-01·Alzheimers & Dementia

The VIVA‐MIND study: Topline Results from Phase 2 RCT of Varoglutamstat in Early AD

Article

作者: Messer, Karen ; Lama, Nicola ; Revta, Carolyn ; Weber, Frank ; Balasubramanian, Archana ; Pol, Alessandra ; Edland, Steven D ; Wenzkowski, Christine ; Jacobs, Diane M. ; Wassmann, Tanja ; Meyer, Antje ; Duehring, Jasmin ; Schell‐Mader, Sylvia ; Leger, Gabriel C ; Schaeffer, Michael ; Zhang, Jing ; Lupo, Jody‐Lynn ; Feldman, Howard H. ; MacKelfresh, Andrew ; Quach, Natalie E

Abstract:

Background:

Varoglutamstat (PQ912) is an oral small molecule inhibitor of glutaminyl cyclases which reduces the pyroglutamate formation of Aβ and CCL2. Preclinical and Ph1 trials support this Ph2 evaluation in early AD. Our objectives included selecting the highest safe and well‐tolerated dose of varoglutamstat with futility analysis at 24 weeks (Ph2A) followed by seamless evaluation of longer‐term safety and efficacy at 72 weeks at this dose (Ph2B).

Method:

Participants with biomarker confirmed early AD were randomized to varoglutamstat or placebo. A sequential design tested 3 descending doses (600mg, 300mg, 150mg BID) using a continuous Pocock safety boundary. A Stage Gate futility analysis of the first 180 subjects at 24 weeks was designed to guide the decision from Ph2A‐B (Figure 1). The Ph2B primary endpoint was CDR‐sum‐of‐boxes (CDR‐SB), with secondary endpoints CFC2, ABC score, spectral EEG, FAQ, ADAS‐Cog‐13, and NPI.

Result:

Table 1 presents baseline characteristics of the 109 randomized and dosed participants. The first dose cohort of varoglutamstat 600mg or placebo did not cross the safety boundary in Ph2A, supporting this dose selection for all participants thereafter. An abbreviated futility analysis was conducted after the trial was terminated prematurely for administrative reasons, with the provisional result of ‘halt enrollment’(yellow) (Figure 1). There were 74% of participants who completed week 24 and 31% week 72 (Figure 2). There were no significant differences between varoglutamstat and placebo in LS mean squares from baseline to week 72 in CDR‐SB (‐0.05 [95% CI ‐1.03, 0.92]), CFC2 (0.97 [95% CI ‐3.34, 5.28]), ABC score (0.10 [95% CI ‐0.10, 0.30]), FAQ (‐0.60 [95% CI ‐4.22, 3.01]), ADAS‐Cog‐13 (2.03 [95% CI ‐2.29, 6.36]); or NPI (‐3.09 [95% CI ‐7.81, 1.62]). At least one TEAE during treatment was reported in 84.9% varoglutamstat and 76.8% placebo with treatment discontinuations due to AE 11.3% varoglutamstat and 3.4% placebo. Severe TEAEs occurred with similar frequencies across arms. Frequency of SAEs/AESIs was 18.9/1.9% varoglutamstat versus 8.9%/5.4% placebo.

Conclusion:

Varoglutamstat was safe and well‐tolerated in this VIVA‐MIND early AD RCT. Efficacy assessment did not demonstrate any significant treatment benefits however, the available sample was limited. Biomarker results and PK/PD are pending.

2025-09-18·JOURNAL OF PHYSICAL CHEMISTRY B

Varoglutamstat Inhibits the Dimerization of the Aβ_25–35 Fragment in Aqueous Solution

Article

作者: Van V. Vu ; Son Tung Ngo ; Trung Hai Nguyen ; Philippe Derreumaux ; Hoang Anh Nguyen

The self-aggregation of amyloid-beta (Aβ) peptides is strongly associated with Alzheimer's disease. In this study, the influence of the small varoglutamstat compound on the conformations of the FAβ_25-35 dimer was extensively characterized by using MD simulations. The influence of the ligand on the conformation of the FAβ_25-35 dimer was studied during the first 10.0 μs. However, its real influence was clarified when the trajectory was extended to 20.0 μs. This indicates that the investigation of a ligand inhibiting Aβ requires a longer MD simulation than previously thought. The ligand changes ensemble properties by reducing the formation of nonbonded intermolecular contacts and β-content. Although varoglutamstat has weak binding to the FAβ_25-35 dimer, the free energy landscape is impacted in shape, free energy barrier, and number of minima. Notably, it is found that the population of the amyloid-competent dimer structure is substantially reduced upon ligand addition. Furthermore, the change from β-hairpin conformation to antiparallel structure may occur through a transition state forming a random coil conformation.

项与 Varoglutamstat 相关的新闻（医药）

2026-04-15

·BioSpace

Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026

Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026 Halle (Saale) / Munich, Germany, April 15 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will report full year 2025 financial results and business updates on Thursday, April 23, 2026. The Company will host a conference call and webcast open to the public. The report will be available for download on the Company's website ( ). Conference call details Date: April 23, 2026 Time: 3:00 pm CEST / 9:00 am EDT The conference call will be available via phone and webcast. The live audio webcast of the call will be available on Vivoryon´s website at: To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website: It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance. ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. Vivoryon Forward Looking Statements This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Vivoryon Therapeutics N.V. Dr. Manuela Bader, Director IR & Communication Email: IR@vivoryon.com LifeSci Advisors Sandya von der Weid Tel: +41 78 680 05 38 Email: svonderweid@lifesciadvisors.com Attachment 2026-04-16_FY 2025 NoR

2026-04-09

·BioSpace

Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference

Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference Halle (Saale) / Munich, Germany, April 9 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following investor conference: Van Lanschot Kempen Life Sciences Conference Date: April 16, 2026 Location: Amsterdam, The Netherlands Attendee: Julia Neugebauer, PhD, COO ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. Vivoryon Forward Looking Statements This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Investor Contact Vivoryon Therapeutics N.V. Dr. Manuela Bader, Director IR & Communication Email: IR@vivoryon.com LifeSci Advisors Sandya von der Weid Tel: +41 78 680 05 38 Email: svonderweid@lifesciadvisors.com Attachment 2026-04-09_VVY_kempen

2026-03-28

·GlobeNewswire-Health Care

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology Halle (Saale) / Munich, Germany, March 28, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that new data analyses from the Company’s varoglutamstat Phase 2 program were presented at the World Congress of Nephrology (WCN) held in Yokohama, Japan, March 28-31, 2026. “We are very pleased with the opportunity to share our consistently compelling results with world leading experts in the kidney space at WCN, the International Society of Nephrology’s flagship event,” said Frank Weber, MD, CEO of Vivoryon. “With these new analyses we are able to deliver additional mechanistic proof points showing that inhibition of glutaminyl cyclases can effectively address the underlying molecular changes in diabetic kidney disease. The data continue to strengthen our ongoing development program dedicated to making a meaningful contribution to shaping the future of global kidney care.” Presentation HighlightsVivoryon has thoroughly analyzed kidney function data from the two independent Phase 2 studies VIVIAD and VIVA-MIND, with highly consistent results between the two studies, highlighting the unique potential of varoglutamstat to meaningfully improve kidney function in patients with diabetes. The new analyses presented at WCN underscore previous reports showing that the effect of varoglutamstat on eGFR observed in both studies was greater in elderly participants with diabetes compared to elderly participants without diabetes. In participants with diabetes and lower baseline eGFR (mean 60 mL/min/1.73m2), the effect size was comparable or higher than in the total population of participants with diabetes. Additionally, analysis of data from a DKD mouse model showed significant improvements of inflammation, glomerulosclerosis and kidney function. Taken together, these results add to the growing body of evidence showing that inhibition of glutaminyl cyclases is valid approach to address the underlying inflammatory and fibrotic changes in DKD and support further development of varoglutamstat in patients with diabetes and more advanced CKD stages. Presentation DetailsPresentation Date/Time: March 28, 2026, 5:00 pm JST/9:00 am CET Poster Title: Translational Validation of Glutaminyl-Cyclases as Promising New Target for Treatment of DKD (P334)Venue: Pacifico Yokohama, Yokohama, JapanPresenter: Christine Wenzkowski, PhD, VP Business Development of Vivoryon ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com Vivoryon Forward Looking Statements This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact:Investor ContactVivoryon Therapeutics N.V.Dr. Manuela Bader, Director IR & CommunicationEmail: IR@vivoryon.com LifeSci AdvisorsSandya von der Weid Tel: +41 78 680 05 38Email: svonderweid@lifesciadvisors.com Attachment 2026-03-28_VVY_WCN

临床2期临床结果

100 项与 Varoglutamstat 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
轻度痴呆	临床2期	中国	Vivoryon Therapeutics NV	2022-04-26
轻度痴呆	临床2期	中国	江苏先声药业有限公司	2022-04-26
轻度痴呆	临床2期	中国	Haupt Pharma Wülfing GmbH	2022-04-26
轻度认知障碍	临床2期	丹麦	Vivoryon Therapeutics NV	2020-07-06
轻度认知障碍	临床2期	丹麦	Nordic Bioscience A/S	2020-07-06
轻度认知障碍	临床2期	德国	Vivoryon Therapeutics NV	2020-07-06
轻度认知障碍	临床2期	德国	Nordic Bioscience A/S	2020-07-06
轻度认知障碍	临床2期	荷兰	Nordic Bioscience A/S	2020-07-06
轻度认知障碍	临床2期	荷兰	Vivoryon Therapeutics NV	2020-07-06
轻度认知障碍	临床2期	波兰	Vivoryon Therapeutics NV	2020-07-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03919162 (VIVA-MIND, CTgov)	临床2期	阿尔茨海默症	112	PQ912 (PQ912)	選窪願觸襯鏇觸願獵製 = 醖簾淵憲襯網鹽鬱壓衊膚築範範繭範齋衊鹽構 (膚膚築憲構構齋襯艱積, 廠願餘糧鑰窪鏇鏇鹹積 ~ 蓋鑰鬱醖觸鹹積範鏇選) 更多	-	2025-12-12
				Placebo (Placebo)	選窪願觸襯鏇觸願獵製 = 壓選築廠鹹願憲網構艱膚築範範繭範齋衊鹽構 (膚膚築憲構構齋襯艱積, 艱鑰顧憲窪顧膚餘蓋積 ~ 鬱顧網艱襯鏇鬱鹹鏇構) 更多
NCT03919162 (VIVA-MIND, GlobeNewswire) 人工标引	临床2期	阿尔茨海默症	-	Varoglutamstat	遞簾壓簾鹹襯壓齋築積(憲顧醖構膚齋積範鬱顧) = no clinically meaningful and no statistically significant differences between varoglutamstat 600mg BID and placebo 鏇襯鑰鏇顧繭製鏇繭積 (構鑰齋鏇蓋廠顧鏇鑰蓋 ) 更多	积极	2024-12-09
				placebo
NCT04498650 (VIVIAD, ASN2024)	临床2期	阿尔茨海默症 \| 轻度认知障碍	259	Varoglutamstat 300 mg	網顧窪淵鑰醖衊範鏇積(鹽製窪壓餘繭憲齋觸廠) = 醖蓋鹹遞膚餘構簾衊獵夢願築鏇簾願夢顧顧築 (醖選夢壓憲鹽範齋憲憲 )	积极	2024-10-25
				Varoglutamstat 600 mg	構壓選觸獵餘積鬱襯鏇(膚夢蓋糧網築艱鹽廠淵) = 襯蓋鏇蓋糧壓壓鏇壓淵製鑰繭繭願醖觸糧願廠 (餘憲鏇憲鑰壓製遞夢構 ) 更多
NCT04498650 (VIVIAD, GlobeNewswire \| ASN2024)	临床2期	阿尔茨海默症 \| 糖尿病肾病	32	Varoglutamstat	簾鏇齋鏇窪壓餘餘網餘(選遞積構範憲製製選衊) = 壓蓋製構淵積襯鑰廠夢積鑰網選齋選糧窪壓壓 (醖構選壓窪鑰網積觸築 )	积极	2024-10-25
				placebo	簾鏇齋鏇窪壓餘餘網餘(選遞積構範憲製製選衊) = 範願製鑰壓遞願醖窪鏇積鑰網選齋選糧窪壓壓 (醖構選壓窪鑰網積觸築 )
NCT04498650 (VIVIAD, GlobeNewswire) 人工标引	临床2期	肾脏疾病 CCL2 Expression	-	Varoglutamstat 600mg BID	醖網糧網廠範範築願構(窪構餘網艱糧築製蓋憲) = 願憲製遞鑰窪鑰製糧艱醖衊鹹範壓鏇膚蓋憲鹹 (鑰網艱獵淵憲蓋構衊鬱 ) 更多	积极	2024-09-12
NCT04498650 (VIVIAD, Corporate Publications) 人工标引	临床2期	阿尔茨海默症	250	Varoglutamstat	觸醖構夢夢夢範夢鹹遞(築鬱窪憲鬱廠觸襯蓋艱) = 繭鬱製願窪願鹽壓鑰廠積夢簾壓鬱壓餘願糧簾 (鹹鏇糧餘鏇鏇糧繭壓餘 ) 更多	积极	2022-07-31
NCT02389413 (Pubmed \| Alzheimers Res Ther) 人工标引	临床2期	阿尔茨海默症	120	PQ912	網鹹蓋製鑰襯夢艱餘繭(廠蓋鏇襯壓積齋簾遞鏇) = There was no significant difference between treatments in the number of subjects with (serious) adverse events, although there were slightly more patients with a serious adverse event in the PQ912 group compared to placebo. 鏇壓夢齋築鹹製窪窪夢 (網窪窪窪簾網繭構繭醖 ) 更多	积极	2018-10-12
				Placebo